iORGANBIO Secures Strategic Investment from Mitsui Chemicals for Innovative Drug Discovery

iORGANBIO, a biotech startup from Morrisville, N.C., has announced a strategic investment from Mitsui Chemicals through its $60 million 321Catalyst fund. The partnership combines iORGANBIO's AI-driven CellForge™ platform with Mitsui’s oxygen-permeable cell culture plates. This collaboration arrives post-FDA's regulatory shift away from animal testing, aiming for advanced human-relevant drug testing alternatives.